Effect of hydralazine on CD3-zeta chain expression in Jurkat T cells.
OBJECTIVE
Deficient CD3-zeta chain expression in T cells of patients with idiopathic SLE is associated with T cell receptor/ /CD3 complex (TCR/CD3)-mediated signaling defect. Hydralazine (HYD) inhibits expression of DNA methyltransferase 1 (DNMT1) and may cause a lupus-like disease in man.


METHODS
To explain the HYD effect on intracellular level of CD3-zeta chain in Jurkat T leukemia cells clone E6-1, we employed the flow cytometric analysis.


RESULTS
We observed a dose-dependent increase in cellular content of CD3-zeta chain in Jurkat T cells treated with HYD. Our results suggest that HYD may result in T cells dysfunction different from this observed in idiopathic SLE T cells.


CONCLUSIONS
This difference may partially explain distinct disease course in patients with HYD induced and idiopathic SLE.
Januchowski
R
R
Department of Biochemistry and Molecular Biology, University of Medical Sciences, ul. Swiecickiego 6, 60-781 Poznań, Poland. fagm13@wp.pl
Jagodziński
P P
PP
D017252:CD3 Complex / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D005434:Flow Cytometry; D006801:Humans; D006830:Hydralazine / Q000494:pharmacology*; D019169:Jurkat Cells; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D017252:CD3 Complex; C121704:CD3 antigen, zeta chain; D006830:Hydralazine